Scilex Holding Company (SCLX)

0.8302 -0.0169 (-2.00%) At close: 04:00PM EDT

Scilex Holding Company

960 San Antonio Road
Palo Alto, CA 94303
United States
650 516 4310
https://www.scilexholding.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 105

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Henry H. Ji Ph.D.	Executive Chairman	885.43k	N/A	1964
Dr. Suketu D. Desai Ph.D.	CTO & Senior VP	N/A	N/A	1966
Ms. Gigi DeGuzman	Executive Director of Administrative Operations & Head of Human Resources	N/A	N/A	N/A
Mr. Steven F. Lincoln J.D.	General Counsel & Chief Compliance Officer	N/A	N/A	N/A
Mr. Sumant Rajendran	Executive Director of Marketing	N/A	N/A	N/A
Mike Ciaffi	National Sales Director	N/A	N/A	N/A
Mr. Suresh K. Khemani	Senior VP & Chief Commercial Officer	456.82k	N/A	1960
Dr. Dmitri V. Lissin M.D.	Senior VP & Chief Medical Officer	528.83k	N/A	1960
Dr. Elaine K Chan Pharm.D.	Executive Director & Head of Medical Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Corporate governance

Scilex Holding Company’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.